Biogen | BIIB - Créances Commerciales





Créances Commerciales Changement Date
AbbVie USD 12.77B 132M 2025-09
Acadia Pharmaceuticals USD 148.23M 8.79M 2025-12
ALKERMES USD 334.02M 21.08M 2025-12
Amgen USD 9.57B 1.08B 2025-12
Bayer EUR 14.19B 720M 2025-12
Biogen USD 1.85B 234M 2025-09
BioMarin Pharmaceutical USD 908.21M 117.95M 2025-12
Bristol-Myers Squibb USD 14.62B 485M 2025-09
Eli Lilly USD 19.46B 2.25B 2025-09
Esperion Therapeutics USD 140.19M 21.21M 2025-12
Gilead Sciences USD 4.91B 182M 2025-12
Incyte USD 1.02B 128.52M 2025-12
Merck USD 12.12B 596M 2025-09
Moderna USD 184M 862M 2025-12
Neurocrine Biosciences USD 686.8M 41.2M 2025-12
Novartis USD 12.29B 3.3B 2025-12
Pfizer USD 18.12B 2.02B 2025-09
PTC Therapeutics USD 181.62M 21.45M 2025-12
Puma Biotechnology USD 28.1M 3.52M 2024-06
Regeneron Pharmaceuticals USD 5.74B 54M 2025-12
Sangamo BioSciences USD 581K 110K 2024-06
Sanofi EUR 397M 100M 2025-12
Sanofi EUR 397M 186.13M 2025-12
Sarepta Therapeutics USD 398.23M 2.49M 2025-12
Teva Pharmaceutical Industries USD 3.71B 101M 2025-12
Ultragenyx Pharmaceutical USD 112.54M 11.92M 2025-09
United Therapeutics USD 350.2M 52.5M 2025-12
Vertex Pharmaceuticals USD 2.05B 106.4M 2025-12